研究について

研究について

業績一覧

生化学グループ

  • ～2022年度
  • Yamagata H, Tsunedomi R, Kamishikiryo T, Kobayashi A, Seki T, Kobayashi M, Hagiwara K, Yamada N, Chen C, Uchida S, Ogihara H, Hamamoto Y, Okada G, Fuchikami M, Iga JI, Numata S, Kinoshita M, Kato TA, Hashimoto R, Nagano H, Ueno S, Okamoto Y, Ohmori T, Nakagawa S (2023) Interferon signaling and hypercytokinemia-related gene expression in the blood of antidepressant non-responders. Heliyon 9, e13059.
  • Yoshino Y, Kumon H, Shimokawa T, Yano H, Ochi S, Funahashi Y, Iga JI, Matsuda S, Tanaka J, Ueno SI (2022) Impact of Gestational Haloperidol Exposure on miR-137-3p and Nr3c1 mRNA Expression in Hippocampus of Offspring Mice. Int J Neuropsychopharmacol 25, 853-862.
  • Kumon H, Miyake Y, Yoshino Y, Iga JI, Tanaka K, Senba H, Kimura E, Higaki T, Matsuura B, Kawamoto R, Ueno SI (2022) Functional AGXT2 SNP rs37369 Variant Is a Risk Factor for Diabetes Mellitus: Baseline Data From the Aidai Cohort Study in Japan. Can J Diabetes 46, 829-834.
  • Funahashi Y, Yoshino Y, Iga JI, Ueno SI (2022) Impact of clozapine on the expression of miR-675-3p in plasma exosomes derived from patients with schizophrenia. World J Biol Psychiatry, 1-11.
  • Yamagata H, Kobayashi A, Tsunedomi R, Seki T, Kobayashi M, Hagiwara K, Chen C, Uchida S, Okada G, Fuchikami M, Kamishikiryo T, Iga JI, Numata S, Kinoshita M, Kato TA, Hashimoto R, Nagano H, Okamoto Y, Ueno S, Ohmori T, Nakagawa S (2021) Optimized protocol for the extraction of RNA and DNA from frozen whole blood sample stored in a single EDTA tube. Sci Rep 11, 17075.
  • ～2021年度
  • Effects of AGXT2 variants on blood pressure and blood sugar among 750 older Japanese subjects recruited by the complete enumeration survey method. Yoshino Y, Kumon H, Mori T, Yoshida T, Tachibana A, Shimizu H, Iga JI, Ueno SI. BMC Genomics. 2021 Apr 20;22(1):287. doi: 10.1186/s12864-021-07612-3.
  • Neural precursor cells are decreased in the hippocampus of the delayed carbon monoxide encephalopathy rat model. Ochi S, Sekiya K, Abe N, Funahashi Y, Kumon H, Yoshino Y, Nishihara T, Boku S, Iga JI, Ueno SI. Sci Rep. 2021 Mar 18;11(1):6244. doi: 10.1038/s41598-021-85860-9.
  • Positional cloning and comprehensive mutation analysis identified a novel KDM2B mutation in a Japanese family with minor malformations, intellectual disability, and schizophrenia. Yokotsuka-Ishida S, Nakamura M, Tomiyasu Y, Nagai M, Kato Y, Tomiyasu A, Umehara H, Hayashi T, Sasaki N, Ueno SI, Sano A. J Hum Genet. 2021 Jun;66(6):597-606. doi: 10.1038/s10038-020-00889-4. Epub 2021 Jan 6.
  • PICALM mRNA Expression in the Blood of Patients with Neurodegenerative Diseases and Geriatric Depression. Kumon H, Yoshino Y, Funahashi Y, Mori H, Ueno M, Ozaki Y, Yamazaki K, Ochi S, Mori T, Iga JI, Nagai M, Nomoto M, Ueno SI. J Alzheimers Dis. 2021;79(3):1055-1062. doi: 10.3233/JAD-201046.
  • Positional cloning and comprehensive mutation analysis of a Japanese family with lithium-responsive bipolar disorder identifies a novel DOCK5 mutation. Umehara H, Nakamura M, Nagai M, Kato Y, Ueno SI, Sano A. J Hum Genet. 2021 Mar;66(3):243-249. doi: 10.1038/s10038-020-00840-7. Epub 2020 Sep 12.
  • Identifying Blood Transcriptome Biomarkers of Alzheimer’s Disease Using Transgenic Mice. Ochi S, Iga JI, Funahashi Y, Yoshino Y, Yamazaki K, Kumon H, Mori H, Ozaki Y, Mori T, Ueno SI. Mol Neurobiol. 2020 Dec;57(12):4941-4951. doi: 10.1007/s12035-020-02058-2. Epub 2020 Aug 20.
  • CTLA4 mRNA expression in blood is lower in schizophrenia, but not in affective disorders. Miyamoto K, Funahashi Y, Yoshino Y, Kawabe K, Yamazaki K, Ozaki Y, Mori Y, Ochi S, Iga JI, Ueno SI. Asian J Psychiatr. 2020 Aug;52:102112. doi: 10.1016/j.ajp.2020.102112. Epub 2020 Apr 19.
  • ABCA7 Gene Expression and Genetic Association Study in Schizophrenia. Yamazaki K, Yoshino Y, Kawabe K, Ibuki T, Ochi S, Mori Y, Ozaki Y, Numata S, Iga JI, Ohmori T, Ueno SI. Neuropsychiatr Dis Treat. 2020 Feb 13;16:441-446. doi: 10.2147/NDT.S238471. eCollection 2020.
  • DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson’s disease. Ozaki Y, Yoshino Y, Yamazaki K, Ochi S, Iga JI, Nagai M, Nomoto M, Ueno SI. Acta Neurol Scand. 2020 Feb;141(2):177-182. doi: 10.1111/ane.13186. Epub 2019 Nov 16.
  • Analysis of methylation and -141C Ins/Del polymorphisms of the dopamine receptor D2 gene in patients with schizophrenia. Funahashi Y, Yoshino Y, Yamazaki K, Ozaki Y, Mori Y, Mori T, Ochi S, Iga JI, Ueno SI. Psychiatry Res. 2019 Aug;278:135-140. doi: 10.1016/j.psychres.2019.06.001. Epub 2019 Jun 1.
  • Differential expression of the ghrelin-related mRNAs GHS-R1a, GHS-R1b, and MBOAT4 in Japanese patients with schizophrenia. Nakata S, Yoshino Y, Okita M, Kawabe K, Yamazaki K, Ozaki Y, Mori Y, Ochi S, Iga JI, Ueno SI. Psychiatry Res. 2019 Feb;272:334-339. doi: 10.1016/j.psychres.2018.12.135. Epub 2018 Dec 26.
  • Ghrelin cascade changes in the peripheral blood of Japanese patients with Alzheimer’s disease. Yoshino Y, Funahashi Y, Nakata S, Ozaki Y, Yamazaki K, Yoshida T, Mori T, Mori Y, Ochi S, Iga JI, Ueno SI. J Psychiatr Res. 2018 Dec;107:79-85. doi: 10.1016/j.jpsychires.2018.10.011. Epub 2018 Oct 18.
  • TREM1 mRNA Expression in Leukocytes and Cognitive Function in Japanese Patients with Alzheimer’s Disease. Sao T, Yoshino Y, Yamazaki K, Ozaki Y, Mori Y, Ochi S, Yoshida T, Mori T, Iga JI, Ueno SI. J Alzheimers Dis . 2018;64(4):1275-1284. doi: 10.3233/JAD-180418.
  • MEF2C mRNA expression and cognitive function in Japanese patients with Alzheimer’s disease. Sao T, Yoshino Y, Yamazaki K, Ozaki Y, Mori Y, Ochi S, Yoshida T, Mori T, Iga JI, Ueno SI. Psychiatry Clin Neurosci. 72:160-167, 2018.
  • TOMM40 and APOE Gene Expression and Cognitive Decline in Japanese Alzheimer’s Disease Subjects. Mise A, Yoshino Y, Yamazaki K, Ozaki Y, Sao T, Yoshida T, Mori T, Mori Y, Ochi S, Iga JI, Ueno SI. J Alzheimers Dis. 60: 1107–1117, 2017.
  • DNA Methylation Changes in Intron 1 of Triggering Receptor Expressed on Myeloid Cell 2 in Japanese Schizophrenia Subjects. Yoshino Y, Ozaki Y, Yamazaki K, Sao T, Mori Y, Ochi S, Iga JI, Ueno SI. Front Neurosci. 11: 275, 2017.
  • INPP5D mRNA Expression and Cognitive Decline in Japanese Alzheimer’s Disease Subjects. Yoshino Y, Yamazaki K, Ozaki Y, Sao T, Yoshida T, Mori T, Mori Y, Ochi S, Iga JI, Ueno SI. J Alzheimers Dis. 58: 687-694, 2017.
  • Elevated mRNA expression of CASPR3 in patients with schizophrenia. Okita M, Yoshino Y, Iga JI, Ueno SI. Nord J Psychiatry 71:312-314, 2017.
  • DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer’s disease. Ozaki Y, Yoshino Y, Yamazaki K, Sao T, Mori Y, Ochi S, Yoshida T, Mori T, Iga JI, Ueno SI. J Psychiatr Res 92:74-80, 2017.
  • Gene Expression and Methylation Analysis of ABCA7 in Patients with Alzheimer’s Disease. Yamazaki K, Yoshino Y, Mori T, Yoshida T, Ozaki Y, Sao T, Mori Y, Ochi S, Iga JI, Ueno SI. J Alzheimers Dis 57: 171-181, 2017.
  • DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies. Funahashi Y, Yoshino Y, Yamazaki K, Mori Y, Mori T, Ozaki Y, Sao T, Ochi S, Iga JI, Ueno SI. Psychiatry Clin Neurosci 71:28-35,2017.

神経心理グループ

  • ～2022年度
  • Maki K, Ohara T, Hata J, Shibata M, Hirabayashi N, Honda T, Sakata S, Furuta Y, Akiyama M, Yamasaki K, Tatewaki Y, Taki Y, Kitazono T, Mikami T, Maeda T, Ono K, Mimura M, Nakashima K, Iga JI, Takebayashi M, Ninomiya T, Japan Prospective Studies Collaboration for A, Dementia study g (2023) CKD, Brain Atrophy, and White Matter Lesion Volume: The Japan Prospective Studies Collaboration for Aging and Dementia. Kidney Med 5, 100593.
  • Ueno M, Yoshino Y, Mori H, Funahashi Y, Kumon H, Ochi S, Ozaki T, Tachibana A, Yoshida T, Shimizu H, Mori T, Iga JI, Ueno SI (2022) Association Study and Meta-Analysis of Polymorphisms and Blood mRNA Expression of the ALDH2 Gene in Patients with Alzheimer’s Disease. J Alzheimers Dis 87, 863-871.
  • Shimizu H, Mori T, Yoshida T, Tachibana A, Ozaki T, Yoshino Y, Ochi S, Sonobe N, Matsumoto T, Komori K, Iga JI, Ninomiya T, Ueno SI, Ikeda M (2022) Secular trends in the prevalence of dementia based on a community-based complete enumeration in Japan: the Nakayama Study. Psychogeriatrics 22, 631-641.
  • Ozaki T, Yoshino Y, Tachibana A, Shimizu H, Mori T, Nakayama T, Mawatari K, Numata S, Iga JI, Takahashi A, Ohmori T, Ueno SI (2022) Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer’s disease (from the Nakayama Study). Sci Rep 12, 15205.
  • Ochi S, Mori T, Iga JI, Ueno SI (2022) Prevalence of Comorbid Dementia in Late-life Depression and Bipolar Disorder: A Retrospective Inpatient Study. J Alzheimers Dis Rep 6, 589-598.
  • Mori H, Yoshino Y, Ueno M, Funahashi Y, Kumon H, Ozaki Y, Yamazaki K, Ochi S, Iga Ji, Ueno Si (2022) Blood MAPT expression and methylation status in Alzheimer’s disease. Psychiatry and Clinical Neurosciences Reports 1, e65.
  • Kawakami I, Iga JI, Takahashi S, Lin YT, Fujishiro H (2022) Towards an understanding of the pathological basis of senile depression and incident dementia: Implications for treatment. Psychiatry Clin Neurosci 76, 620-632.
  • Baba H, Kito S, Nukariya K, Takeshima M, Fujise N, Iga J, Oshibuchi H, Kawano M, Kimura M, Mizukami K, Mimura M, Committee for Treatment Guidelines of Mood Disorders JSoMD (2022) Guidelines for diagnosis and treatment of depression in older adults: A report from the Japanese Society of mood disorders. Psychiatry Clin Neurosci 76, 222-234.
  • Ochi S, Mori T, Iga JI, Ueno SI (2021) 5-HT(1A) Partial Agonist Tandospirone for Behavioral and Psychological Symptoms in Oldest-old Patients with Dementia at a Special Elderly Nursing Home. Clin Psychopharmacol Neurosci 19, 514-520.
  • Mori H, Funahashi Y, Yoshino Y, Kumon H, Ozaki Y, Yamazaki K, Ochi S, Tachibana A, Yoshida T, Shimizu H, Mori T, Iga JI, Ueno SI (2021) Blood CDKN2A Gene Expression in Aging and Neurodegenerative Diseases. J Alzheimers Dis 82, 1737-1744.
  • ～2021年度
  • Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan: the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). Ninomiya T, Nakaji S, Maeda T, Yamada M, Mimura M, Nakashima K, Mori T, Takebayashi M, Ohara T, Hata J, Kokubo Y, Uchida K, Taki Y, Kumagai S, Yonemoto K, Yoshida H, Muto K, Momozawa Y, Akiyama M, Kubo M, Ikeda M, Kanba S, Kiyohara Y; JPSFC-AD Study Group. Environ Health Prev Med. 2020 Oct 31;25(1):64. doi: 10.1186/s12199-020-00903-3.
  • Prevalence of possible idiopathic normal pressure hydrocephalus in older inpatients with schizophrenia: a replication study. Yoshino Y, Yoshida T, Morino H, Nakamura M, Abe M, Omachi H, Inoue S, Miyoshi Y, Tachibana Y, Yamauchi N, Takeda N, Mizobuchi M, Ozaki Y, Ochi S, Iga J, Ueno SI. BMC Psychiatry. 2020 Jun 1;20(1):273. doi: 10.1186/s12888-020-02690-1.
  • Improvement of Visuo-spatial Function Assessed by Raven’s Colored Progressive Matrices in Dementia with Lewy Bodies by Donepezil Treatment. Yoshino Y, Mori T, Yoshida T, Toyota Y, Shimizu H, Iga JI, Nishitani S, Ueno SI. Clin Psychopharmacol Neurosci. 15: 243-247, 2017.

児童青年期精神医学グループ

  • ～2022年度
  • Hosokawa R, Kawabe K, Nakachi K, Soga J, Horiuchi F, Ueno SI (2023) Effects of social media on body dissatisfaction in junior high school girls in Japan. Eat Behav 48, 101685.
  • Kawabe K, Horiuchi F, Hosokawa R, Nakachi K, Soga J, Ueno SI (2022) Influence of an Esports Program on Problematic Gaming in Children with Autistic Spectrum Disorder: A Pilot Study. Behav Sci (Basel) 12.
  • Hosokawa R, Yoshino Y, Funahashi Y, Horiuchi F, Iga JI, Ueno SI (2022) MiR-15b-5p Expression in the Peripheral Blood: A Potential Diagnostic Biomarker of Autism Spectrum Disorder. Brain Sci 13.
  • Horiuchi F, Yoshino-Ozaki A, Hattori H, Hosokawa R, Nakachi K, Ito R, Miyama T, Tachibana Y, Inoue S, Kawabe K, Ueno S (2022) Expression of overadaptation in children through drawing a man as a projective measure: a community sample study. Pediatr Int 64, e14919.
  • Nakachi K, Kawabe K, Hosokawa R, Yoshino A, Horiuchi F, Ueno SI (2021) Differences in Psychological and Behavioral Changes between Children following School Closure due to COVID-19. Psychiatry J 2021, 5567732.
  • Hosokawa R, Kawabe K, Nakachi K, Yoshino A, Horiuchi F, Ueno SI (2021) Behavioral Affect in Children with Autism Spectrum Disorder during School Closures Due to the COVID-19 Pandemic in Japan: A Case-Controlled Study. Dev Neuropsychol 46, 288-297.
  • ～2021年度
  • Mental health and sleep habits/problems in children aged 3-4 years: a population study. Horiuchi F, Kawabe K, Oka Y, Nakachi K, Hosokawa R, Ueno SI. Biopsychosoc Med. 2021 May 20;15(1):10. doi: 10.1186/s13030-021-00213-2.
  • Association between Internet Addiction and Application Usage among Junior High School Students: A Field Survey. Kawabe K, Horiuchi F, Hosokawa R, Nakachi K, Ueno SI. Int J Environ Res Public Health. 2021 May 1;18(9):4844. doi: 10.3390/ijerph18094844.
  • Identification of aberrant innate and adaptive immunity based on changes in global gene expression in the blood of adults with autism spectrum disorder. Horiuchi F, Yoshino Y, Kumon H, Hosokawa R, Nakachi K, Kawabe K, Iga JI, Ueno SI. J Neuroinflammation. 2021 Apr 30;18(1):102. doi: 10.1186/s12974-021-02154-7.
  • Parent-Adolescent Agreement on Adolescents’ Emotional and Behavioral Problems Assessed by the Strengths and Difficulties Questionnaire. Kawabe K, Horiuchi F, Uno H, Nakachi K, Hosokawa R, Oka Y, Ueno SI. Glob Pediatr Health. 2021 Mar 12;8:2333794X211001245. doi: 10.1177/2333794X211001245. eCollection 2021.
  • The Association between Autistic Traits and Sleep Habits/Problems in Toddlers. Horiuchi F, Kawabe K, Oka Y, Nakachi K, Hosokawa R, Ueno SI. Dev Neuropsychol. 2020 Dec 18;45(7-8):485-495. doi: 10.1080/87565641.2020.1865357. Epub 2020 Dec 25.
  • Excessive and Problematic Internet Use During the Coronavirus Disease 2019 School Closure: Comparison Between Japanese Youth With and Without Autism Spectrum Disorder. Kawabe K, Hosokawa R, Nakachi K, Yoshino A, Horiuchi F, Ueno SI. Front Public Health. 2020 Dec 17;8:609347. doi: 10.3389/fpubh.2020.609347. eCollection 2020.
  • Prevalence of Internet addiction in Japan: Comparison of two cross-sectional surveys. Kawabe K, Horiuchi F, Nakachi K, Hosokawa R, Ueno SI. Pediatr Int. 2020 Aug;62(8):970-975. doi: 10.1111/ped.14250. Epub 2020 Jul 28.
  • Sleep Habits and Electronic Media Usage in Japanese Children: A Prospective Comparative Analysis of Preschoolers. Horiuchi F, Oka Y, Kawabe K, Ueno SI. Int J Environ Res Public Health. 2020 Jul 17;17(14):5189. doi: 10.3390/ijerph17145189.
  • Making a brochure about coronavirus disease (COVID-19) for children with autism spectrum disorder and their family members. Kawabe K, Hosokawa R, Nakachi K, Yoshino A, Horiuchi F, Ueno SI. Psychiatry Clin Neurosci. 2020 Sep;74(9):498-499. doi: 10.1111/pcn.13090. Epub 2020 Jul 10.
  • School refusal and bullying in children with autism spectrum disorder. Ochi M, Kawabe K, Ochi S, Miyama T, Horiuchi F, Ueno SI. Child Adolesc Psychiatry Ment Health. 2020 May 7;14:17. doi: 10.1186/s13034-020-00325-7. eCollection 2020.
  • Combination treatment with guanfacine extended release and blonanserin for Tourette’s syndrome comorbid with attention deficit hyperactivity disorder. Kawabe K, Horiuchi F, Ueno SI. Psychiatry Clin Neurosci. 2019 Dec;73(12):762-763. doi: 10.1111/pcn.12935. Epub 2019 Oct 23.
  • Association between Sleep Habits and Problems and Internet Addiction in Adolescents. Kawabe K, Horiuchi F, Oka Y, Ueno SI. Psychiatry Investig. 2019 Aug;16(8):581-587. doi: 10.30773/pi.2019.03.21.2. Epub 2019 Aug 8.
  • Internet addiction and attention-deficit / hyperactivity disorder symptoms in adolescents with autism spectrum disorder. Kawabe K, Horiuchi F, Miyama T, Jogamoto T, Aibara K, Ishii E, Ueno SI. Res Dev Disabil. 2019 Jun;89:22-28. doi: 10.1016/j.ridd.2019.03.002. Epub 2019 Mar 14.
  • Neurocognitive assessment of children with neurodevelopmental disorders: Preliminary findings. Kawabe K, Horiuchi F, Kondo S, Matsumoto M, Seo K, Oka Y, Ueno SI. Pediatr Int. 2018 Sep;60(9):820-827. doi: 10.1111/ped.13662.
  • Suvorexant for the Treatment of Insomnia in Adolescents. Kawabe K, Horiuchi F, Ochi M, Nishimoto K, Ueno SI, Oka Y. J Child Adolesc Psychopharmacol. 27: 792-795, 2017.

その他

  • ～2022年度
  • Tsuboi T, Takaesu Y, Hasegawa N, Ochi S, Fukumoto K, Ohi K, Muraoka H, Okada T, Kodaka F, Igarashi S, Iida H, Kashiwagi H, Hori H, Ichihashi K, Ogasawara K, Hashimoto N, Iga JI, Nakamura T, Usami M, Nagasawa T, Kido M, Komatsu H, Yamagata H, Atake K, Furihata R, Kikuchi S, Horai T, Takeshima M, Hirano Y, Makinodan M, Matsumoto J, Miura K, Hishimoto A, Numata S, Yamada H, Yasui-Furukori N, Inada K, Watanabe K, Hashimoto R (2023) Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysis. Psychiatry Clin Neurosci 77, 30-37.
  • Iida H, Okada T, Nemoto K, Hasegawa N, Numata S, Ogasawara K, Miura K, Matsumoto J, Hori H, Iga JI, Ichihashi K, Hashimoto N, Yamada H, Ohi K, Yasui-Furukori N, Fukumoto K, Tsuboi T, Usami M, Furihata R, Takaesu Y, Hishimoto A, Muraoka H, Katsumoto E, Nagasawa T, Ochi S, Komatsu H, Kikuchi S, Takeshima M, Onitsuka T, Tamai S, Kubota C, Inada K, Watanabe K, Kawasaki H, Hashimoto R (2023) Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the “Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)” project. Neuropsychopharmacol Rep 43, 23-32.
  • Yasui-Furukori N, Muraoka H, Hasegawa N, Ochi S, Numata S, Hori H, Hishimoto A, Onitsuka T, Ohi K, Hashimoto N, Nagasawa T, Takaesu Y, Inagaki T, Tagata H, Tsuboi T, Kubota C, Furihata R, Iga JI, Iida H, Miura K, Matsumoto J, Yamada H, Watanabe K, Inada K, Shimoda K, Hashimoto R (2022) Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep 42, 3-9.
  • Yamada H, Motoyama M, Hasegawa N, Miura K, Matsumoto J, Ohi K, Yasui-Furukori N, Numata S, Takeshima M, Sugiyama N, Nagasawa T, Kubota C, Atake K, Tsuboi T, Ichihashi K, Hashimoto N, Inagaki T, Takaesu Y, Iga JI, Hori H, Onitsuka T, Komatsu H, Hishimoto A, Fukumoto K, Fujimoto M, Nakamura T, Nemoto K, Furihata R, Yamamura S, Yamagata H, Ogasawara K, Katsumoto E, Murata A, Iida H, Ochi S, Makinodan M, Kido M, Kishimoto T, Yasuda Y, Usami M, Suwa T, Inada K, Watanabe K, Hashimoto R (2022) A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. BJPsych Open 8, e83.
  • Tajika A, Hori H, Iga JI, Koshikawa Y, Ogata H, Ogawa Y, Watanabe K, Kato T, Matsuo K, Kato M (2022) Mood Stabilizers and Antipsychotics for Acute Mania: Systematic Review and Meta-Analysis of Augmentation Therapy vs Monotherapy From the Perspective of Time to the Onset of Treatment Effects. Int J Neuropsychopharmacol 25, 839-852.
  • Okada T, Hori H, Hasegawa N, Murata A, Kyou Y, Kodaka F, Iida H, Ochi S, Takaesu Y, Tsuboi T, Iga JI, Ichihashi K, Muraoka H, Furihata R, Yasui-Furukori N, Usami M, Onitsuka T, Ogasawara K, Tagata H, Takeshima M, Ohi K, Numata S, Hashimoto N, Yamada H, Makinodan M, Komatsu H, Hishimoto A, Yamagata H, Kido M, Kubota C, Atake K, Yamada H, Nagasawa T, Matsumoto J, Miura K, Inada K, Watanabe K, Suda S, Hashimoto R (2022) Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia. J Clin Psychopharmacol 42, 591-593.
  • Ogasawara K, Numata S, Hasegawa N, Nakataki M, Makinodan M, Ohi K, Takeshima M, Tsuboi T, Hashimoto N, Onitsuka T, Muraoka H, Hori H, Ichihashi K, Inagaki T, Yasui-Furukori N, Hishimoto A, Sugiyama N, Fukumoto K, Nagasawa T, Matsumoto J, Takaesu Y, Furihata R, Nemoto K, Nakamura T, Usami M, Miura K, Fujimoto M, Tagata H, Yamada H, Komatsu H, Ochi S, Atake K, Katsumoto E, Kido M, Kishimoto T, Suwa T, Yamamura S, Iga JI, Iida H, Inada K, Watanabe K, Hashimoto R (2022) Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacol Rep 42, 221-225.
  • Ochi S, Tagata H, Hasegawa N, Yasui-Furukori N, Iga JI, Kashiwagi H, Kodaka F, Komatsu H, Tsuboi T, Tokutani A, Numata S, Ichihashi K, Onitsuka T, Muraoka H, Iida H, Ohi K, Atake K, Kishimoto T, Hori H, Takaesu Y, Takeshima M, Usami M, Makinodan M, Hashimoto N, Fujimoto M, Furihata R, Nagasawa T, Yamada H, Matsumoto J, Miura K, Kido M, Hishimoto A, Ueno SI, Watanabe K, Inada K, Hashimoto R (2022) Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study. Int J Neuropsychopharmacol 25, 818-826.
  • Kyou Y, Yasui-Furukori N, Hasegawa N, Ide K, Ichihashi K, Hashimoto N, Hori H, Shimizu Y, Imamura Y, Muraoka H, Iida H, Ohi K, Yasuda Y, Ogasawara K, Numata S, Iga JI, Tsuboi T, Ochi S, Kodaka F, Furihata R, Onitsuka T, Makinodan M, Komatsu H, Takeshima M, Kubota C, Hishimoto A, Atake K, Yamagata H, Kido M, Nagasawa T, Usami M, Kishimoto T, Kikuchi S, Matsumoto J, Miura K, Yamada H, Watanabe K, Inada K, Hahimoto R (2022) The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the “Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)” project. Ann Gen Psychiatry 21, 52.
  • Ishigooka J, Nakagome K, Ohmori T, Iwata N, Inada K, Iga JI, Kishi T, Fujita K, Kikuchi Y, Shichijo T, Tabuse H, Koretsune S, Terada H, Terada H, Kishimoto T, Tsutsumi Y, Kanda Y, Ohi K, Sekiyama K (2022) Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. Psychiatry Clin Neurosci 76, 22-31.
  • Inada K, Fukumoto K, Hasegawa N, Yasuda Y, Yamada H, Hori H, Ichihashi K, Iida H, Ohi K, Muraoka H, Kodaka F, Ide K, Hashimoto N, Iga JI, Ogasawara K, Atake K, Takaesu Y, Nagasawa T, Komatsu H, Okada T, Furihata R, Kido M, Kikuchi S, Kubota C, Makinodan M, Ochi S, Takeshima M, Yamagata H, Matsumoto J, Miura K, Usami M, Kishimoto T, Onitsuka T, Katsumoto E, Hishimoto A, Numata S, Yasui-Furukori N, Watanabe K, Hashimoto R (2022) Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia”. Neuropsychopharmacol Rep 42, 502-509.
  • Ichihashi K, Kyou Y, Hasegawa N, Yasui-Furukori N, Shimizu Y, Hori H, Hashimoto N, Ide K, Imamura Y, Yamada H, Ochi S, Iga JI, Takaesu Y, Ohi K, Tsuboi T, Iida H, Yamagata H, Hishimoto A, Horai T, Usami M, Makinodan M, Nagasawa T, Komatsu H, Kido M, Muraoka H, Atake K, Takeshima M, Kubota C, Inagaki T, Tamai S, Kishimoto T, Furihata R, Matsumoto J, Miura K, Inada K, Watanabe K, Kasai K, Hashimoto R (2022) The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. Asian J Psychiatr 69, 103007.
  • Hori H, Yasui-Furukori N, Hasegawa N, Iga JI, Ochi S, Ichihashi K, Furihata R, Kyo Y, Takaesu Y, Tsuboi T, Kodaka F, Onitsuka T, Okada T, Murata A, Kashiwagi H, Iida H, Hashimoto N, Ohi K, Yamada H, Ogasawara K, Yasuda Y, Muraoka H, Usami M, Numata S, Takeshima M, Yamagata H, Nagasawa T, Tagata H, Makinodan M, Kido M, Katsumoto E, Komatsu H, Matsumoto J, Kubota C, Miura K, Hishimoto A, Watanabe K, Inada K, Kawasaki H, Hashimoto R (2022) Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics. Front Psychiatry 13, 823826.
  • Aoki Y, Takaesu Y, Baba H, Iga JI, Hori H, Inoue T, Mishima K, Tajika A, Kato M (2022) Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission. Neuropsychopharmacol Rep 42, 306-314.
  • Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, Shinohara K, Imai H, Murata A, Mishima K, Tajika A (2021) Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry 26, 118-133.
  • Japanese Society of N (2021) Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”. Neuropsychopharmacol Rep 41, 266-324.
  • Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, Matsumoto J, Murata A, Ogasawara K, Yamada H, Hori H, Ichihashi K, Hashimoto N, Ohi K, Yasui-Furukori N, Tsuboi T, Nakamura T, Usami M, Furihata R, Takaesu Y, Iwamoto K, Sugiyama N, Kishimoto T, Tsujino N, Yamada H, Hishimoto A, Nemoto K, Atake K, Muraoka H, Katsumoto E, Oishi S, Inagaki T, Ito F, Imamura Y, Kido M, Nagasawa T, Numata S, Ochi S, Iwata M, Yamamori H, Fujita J, Onitsuka T, Yamamura S, Makinodan M, Fujimoto M, Takayanagi Y, Takezawa K, Komatsu H, Fukumoto K, Tamai S, Yamagata H, Kubota C, Horai T, Inada K, Watanabe K, Kawasaki H, Hashimoto R (2020) Unmet needs of patients with major depressive disorder – Findings from the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci 74, 667-669.
  • Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, Iwamoto K, Kishimoto T, Horai T, Yamada H, Sugiyama N, Nakamura T, Tsujino N, Nemoto K, Oishi S, Usami M, Katsumoto E, Yamamori H, Tomita H, Suwa T, Furihata R, Inagaki T, Fujita J, Onitsuka T, Miura K, Matsumoto J, Ohi K, Matsui Y, Takaesu Y, Hashimoto N, Iga J, Ogasawara K, Yamada H, Watanabe K, Inada K, Hashimoto R (2020) Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project. Neuropsychopharmacol Rep 40, 281-286.

日本語文献

  • 愛媛大学病院精神科外来における成人期発達障害に対する診療パスの予備的研究 河邉憲太郎，越智麻里奈，松本美希，近藤静香，伊藤瑠璃子，芳野歩美，妹尾香苗，堀内史枝，上野修一 精神医学 60巻 5号 Page 545－557 (2018.05)
  • 非寛解うつ病に対して切り替えか，増強かー高齢者の非寛解うつ病で考えておきたいこと 越智紳一郎, 上野修一 臨床精神薬理 20巻 5号 Page 585-588 (2017.05)
  • うつ病維持療法ガイドライン 伊賀淳一 臨床精神薬理 20巻 5号 Page 505-512 (2017.5)
facebook
Return TOP